Although the incidence of endometrial cancer in African-American (AA) women is lower than in Caucasian (C) women, a striking racial disparity exists in endometrial cancer survival rates in the United States, with blacks having up to 30% worse survival rates than whites. Socio-demographic factors alone cannot account for this difference because differences in survival still occur when analyses are adjusted for black and white women by stage and by biologically aggressive (i.e., Type II) endometrial tumors. Uterine serous papillary carcinoma (USC), represents the most aggressive histologic subtype of endometrial cancer. This variant of endometrial carcinoma is up to three fold more frequent in AA women when compared to C women. On the basis of our recently published data on the genetic landscape of USC suggesting that genetic and biologic factors may underlie the racial disparity in survival rates and with the ultimate goal to develop novel, more specific and more effective treatment modalities for the diagnosis and therapy of USC so common in AA women, we propose the following:
Aim 1 : Identify through whole exome sequencing driver mutation candidates, loss of heterozygosity (LOH) patterns and copy number variations (CNV) in 200 USC samples and use bioinformatics strategies to perform a systematic assessment of genetic differences between AA vs C tumors, Aim 2: Evaluate miRNAs and mRNA expression differences in USC from AA and C and perform downstream analysis of pathways influencing disease in different groups of USC (i.e., c-erbB2+ vs negative and PIK3CA and CCNE1 mutants vs wild type) and Aim 3: Evaluate the biochemical properties of a subset of novel PIK3CA mutations and validate the c-erbB2/PIK3CA and CCNE1 pathways as novel targets for USC treatment using primary USC cell lines and targeted agents including trastuzumab and T-DM1 (i.e., mAbs targeting c-erbB2), AZD8055, GDC-0980 and CYC065 (i.e., a mTOR/PI3K/CDK inhibitors) in in vitro and in vivo assays. This proposal encompasses the first integrated analysis of genomic differences in USC developed by AA when compared to C women as well as the validation of the currently identified differentially expressed genes harboring key driver mutations as novel targets for USC therapy in minority. Relevance Definition and functional validation of key driver mutations and downstream signaling pathways differentially active in AA women harboring USC may be used to guide novel, highly effective targeted therapies against these highly aggressive tumors and, therefore, may have immediate clinical relevance on minority health.

Public Health Relevance

Type II endometrial tumors such as uterine serous carcinoma (USC) are more commonly diagnosed in AA women when compared to C women, suggesting a genetic predisposition in black women to develop these biologically aggressive neoplasms. This proposal is designed to perform the first comprehensive analysis of genomic differences in USC developed by AA women when compared to C women. We will search for driver gene mutations, loss of heterozygosity (LOH) and copy number variations (CNV) and identify miRNAs and genes highly differentially expressed in USC developed by AA women when compared to C women. These studies will provide essential information for a better understanding of the genetic cause of the disparity in frequency of this diagnosis in AA women as well as the molecular basis responsible for the unfavorable prognosis more frequent in AA women relative to C women. Finally, our results will provide essential information for the development of USC-specific therapies for preventing progression of advanced/recurrent disease after conventional surgery and chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA176067-02
Application #
8852574
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Li, Jerry
Project Start
2014-06-01
Project End
2019-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Yale University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Han, Chanhee; Bellone, Stefania; Siegel, Eric R et al. (2018) A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol 149:585-591
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res 23:5836-5845
Carvajal-Hausdorf, Daniel E; Schalper, Kurt A; Bai, Yalai et al. (2017) Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecol Oncol 145:154-158
Roque, Dana M; Santin, Alessandro D (2017) Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. Expert Rev Clin Immunol 13:175-180
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol 146:179-186
Tassi, Renata A; Todeschini, Paola; Siegel, Eric R et al. (2017) FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res 36:63
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol 147:145-152

Showing the most recent 10 out of 42 publications